These subpopulations were not consistently associated with clinicopathologic features such as age, gender, and International Prognostic Index (IPI) Risk Group, nor were they associated with MYC/BCL2/BCL6 translocation status (Supplementary Table S3; Fig. 1F), confirming previous observations that translocations do not account for the majority of MYC, BCL2, and BCL6 overexpression in DLBCL (11). This evidence concerns the gene BCL6 and diffuse large B-cell lymphoma.